Belantamab mafodotin Clinical Trials (2026): 69 Studies for Multiple Myeloma & Refractory Multiple Myeloma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
69 Belantamab mafodotin clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 19 indications (including Multiple Myeloma & Refractory Multiple Myeloma) and 6,011 total planned enrollment. 10 Phase 3 Belantamab mafodotin trials and 18 Phase 2 are listed. 21 Belantamab mafodotin clinical trials are actively recruiting at 93 U.S. sites across 29 states. Most recent activity: NCT07285239 (Jun 2034).
Where to Participate: All Belantamab mafodotin Trial Sites in the U.S. (93 sites across 29 states)
Every actively recruiting Belantamab mafodotintrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | GSK Investigational Site | Mobile36607 | NCT06679101 | Map |
| AZ | GSK Investigational Site | Phoenix85054 | NCT06679101 | Map |
| CA | GSK Investigational Site | Beverly Hills90211 | NCT06679101 | Map |
| CA | GSK Investigational Site | Los Alamitos90720 | NCT07227311 | Map |
| CA | GSK Investigational Site | Pasadena91105 | NCT06679101 | Map |
| CA | GSK Investigational Site | Torrance90505 | NCT07227311 | Map |
| CA | GSK Investigational Site | Whittier90602 | NCT07227311 | Map |
| CO | GSK Investigational Site | Aurora80012 | NCT06679101 | Map |
| DC | GSK Investigational Site | Washington D.C.20007 | NCT06679101 | Map |
| FL | GSK Investigational Site | Englewood34223 | NCT06679101 | Map |
| FL | GSK Investigational Site | Fort Myers33912 | NCT07227311 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05847569 | Map |
| FL | GSK Investigational Site | Lady Lake32159 | NCT06679101 | Map |
| FL | GSK Investigational Site | Pembroke Pines33024 | NCT06679101 | Map |
| FL | GSK Investigational Site | Saint Augustine32256 | NCT06679101 | Map |
| GA | Emory University/Winship Cancer Institute | Atlanta30322 | NCT05208307 | Map |
| GA | GSK Investigational Site | Atlanta30322 | NCT06679101 | Map |
| GA | Winship Cancer Institute of Emory University- Site Number : 8400010 | Atlanta30322 | NCT04643002 | Map |
| GA | GSK Investigational Site | Macon31210 | NCT07227311 | Map |
| IL | University of Chicago Medicine Comprehensive Cancer Center | Chicago60637 | NCT05789303 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT06232044 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT06232044 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT06232044 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT06232044 | Map |
| ME | GSK Investigational Site | Portland04074 | NCT06679101 | Map |
| MD | GSK Investigational Site | Bethesda20817 | NCT07227311 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05922501 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06232044 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05922501 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT06232044 | Map |
| MA | GSK Investigational Site | Worcester01655 | NCT06679101 | Map |
| MI | GSK Investigational Site | Ann Arbor48103 | NCT06679101 | Map |
| MI | University of Michigan Health System - Ann Arbor- Site Number : 8400004 | Ann Arbor48109 | NCT04643002 | Map |
| MI | GSK Investigational Site | Detroit48201 | NCT06679101 | Map |
| MI | GSK Investigational Site | Grand Rapids49546 | NCT05714839 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT06232044 | Map |
| MO | GSK Investigational Site | Bridgeton63044 | NCT07227311 | Map |
| MO | GSK Investigational Site | Springfield65807 | NCT07227311 | Map |
| MT | GSK Investigational Site | Billings59102 | NCT06679101 | Map |
| NJ | GSK Investigational Site | Hackensack07601 | NCT06679101 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT06232044 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT06232044 | Map |
| NM | GSK Investigational Site | Farmington87401 | NCT07227311 | Map |
| NY | Roswell Park Cancer Institute- Site Number : 8400008 | Buffalo14263 | NCT04643002 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT06232044 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT06232044 | Map |
| NY | GSK Investigational Site | New York10065 | NCT06679101 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06232044 | Map |
| NY | GSK Investigational Site | Stony Brook11790 | NCT06679101 | Map |
| NC | GSK Investigational Site | Chapel Hill27514 | NCT05714839 | Map |
| NC | GSK Investigational Site | Charlotte28204 | NCT06679101 | Map |
| NC | GSK Investigational Site | Winston-Salem27103 | NCT06679101 | Map |
| OH | OhioHealth O'Bleness Hospital | Athens45701 | NCT06232044 | Map |
| OH | Columbus Oncology and Hematology Associates Inc | Columbus43214 | NCT06232044 | Map |
| OH | Doctors Hospital | Columbus43228 | NCT06232044 | Map |
| OH | Grant Medical Center | Columbus43215 | NCT06232044 | Map |
| OH | GSK Investigational Site | Columbus43214 | NCT06679101 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT06232044 | Map |
| OH | The Ohio State University- Site Number : 8400012 | Columbus43210 | NCT04643002 | Map |
| OH | Delaware Health Center-Grady Cancer Center | Delaware43015 | NCT06232044 | Map |
| OH | Grady Memorial Hospital | Delaware43015 | NCT06232044 | Map |
| OH | Columbus Oncology and Hematology Associates | Dublin43016 | NCT06232044 | Map |
| OH | Dublin Methodist Hospital | Dublin43016 | NCT06232044 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT06232044 | Map |
| OH | OhioHealth Marion General Hospital | Marion43302 | NCT06232044 | Map |
| OH | OhioHealth Pickerington Methodist Hospital | Pickerington43147 | NCT06232044 | Map |
| OH | OhioHealth Westerville Medical Campus/Westerville Cancer Center | Westerville43082 | NCT06232044 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06232044 | Map |
| RI | GSK Investigational Site | Providence02903 | NCT06679101 | Map |
| TN | GSK Investigational Site | Chattanooga37404 | NCT05714839 | Map |
| TN | GSK Investigational Site | Nashville37203 | NCT05714839 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT06232044 | Map |
| TX | GSK Investigational Site | Austin78705 | NCT06679101 | Map |
| TX | GSK Investigational Site | Austin78712 | NCT06679101 | Map |
| TX | UT Southwestern Medical Center | Dallas75390 | NCT05145816 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05055063 | Map |
| TX | MD Anderson Cancer Center | Houston77051 | NCT05091372 | Map |
| TX | GSK Investigational Site | Kingwood77339 | NCT06679101 | Map |
| TX | GSK Investigational Site | San Antonio78240 | NCT06679101 | Map |
| TX | GSK Investigational Site | Tyler75702 | NCT06679101 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT06232044 | Map |
| VA | GSK Investigational Site | Fairfax22031 | NCT06679101 | Map |
| WA | GSK Investigational Site | Puyallup98373 | NCT06679101 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT06232044 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06232044 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06232044 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT06232044 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT06232044 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT06232044 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT06232044 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT06232044 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT06232044 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT06232044 | Map |
Belantamab mafodotin clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | available | Total |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 1 | 3 | 2 | 2 | 2 | 1 | 11 | ||
| P1/P2 | 6 | 11 | 3 | 3 | 1 | 1 | 1 | 26 | |
| P2 | 6 | 3 | 3 | 2 | 4 | 18 | |||
| P3 | 1 | 6 | 1 | 1 | 1 | 10 | |||
| N/A | 1 | 1 | 1 | 1 | 4 |
Recruiting Belantamab mafodotin clinical trials (21)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07285239 | PrE1005Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | P3 | Multiple Myeloma | 500 | Jul 2026 |
| NCT05847569 | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma | P2 | Recurrent Multiple Myeloma | 62 | Jan 2024 |
| NCT07224672 | ALANISA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis | P2 | Amyloidosis | 60 | Mar 2026 |
| NCT07609706 | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | P1 | Multiple Myeloma | 20 | Oct 2026 |
| NCT06679101 | DREAMM-10A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | P3 | Multiple Myeloma | 520 | Dec 2024 |
| NCT07614360 | DREAMM-16Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma | P2 | Multiple Myeloma | 120 | Aug 2026 |
| NCT05922501 | ISABELAIsatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | P2 | Relapsed Cancer | 50 | May 2024 |
| NCT07227311 | RRMMA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) | P2 | Multiple Myeloma | 200 | Apr 2026 |
| NCT06232044 | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | P1/P2 | Recurrent Multiple Myeloma | 88 | Apr 2025 |
| NCT05714839 | DREAMM-20A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | P1/P2 | Multiple Myeloma | 152 | Jun 2023 |
| NCT05853965 | BELI(E)VECombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | P1/P2 | Multiple Myeloma | 45 | Jun 2023 |
| NCT05789303 | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | P2 | Multiple Myeloma | 83 | May 2023 |
| NCT05874193 | COSTAA Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma | P2 | Relapsed/Refractory Multiple Myeloma | 33 | May 2026 |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | P1/P2 | Plasma Cell Myeloma Refractory | 258 | Jan 2021 |
| NCT05091372 | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | P2 | Myeloma Multiple | 94 | Dec 2022 |
| NCT05208307 | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | P2 | Plasma Cell Myeloma | 34 | Jul 2022 |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | P1/P2 | AL Amyloidosis | 37 | Feb 2024 |
| NCT07019545 | BONSAIA PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY | P2 | Primary Immune Thrombocytopenia (ITP) | 14 | Jun 2025 |
| NCT05055063 | A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma | P1 | Myeloma | 30 | May 2022 |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | P1/P2 | Multiple Myeloma | 36 | Jul 2023 |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | P1/P2 | Multiple Myeloma | 48 | Oct 2022 |
Belantamab mafodotin clinical trials by indication
Multiple Myeloma (43)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07285239 | PrE1005 | P3 | not yet recruiting | Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma |
| NCT04822337 | — | P1/P2 | active not recruiting | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma |
| NCT07609706 | — | P1 | not yet recruiting | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment |
| NCT06679101 | DREAMM-10 | P3 | recruiting | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) |
| NCT07614360 | DREAMM-16 | P2 | not yet recruiting | Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma |
| NCT07227311 | RRMM | P2 | recruiting | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) |
| NCT05714839 | DREAMM-20 | P1/P2 | recruiting | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments |
| NCT06956170 | DREAMM 8 | P3 | active not recruiting | All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma |
| + 35 more, see All trials below. | ||||
Relapsed/Refractory Multiple Myeloma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05874193 | COSTA | P2 | not yet recruiting | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma |
| NCT04896658 | — | P1/P2 | terminated | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma |
| NCT06655818 | GSK2857916 | P1/P2 | terminated | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM |
| NCT06160609 | GSK2857916 | P1/P2 | terminated | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM |
Plasma Cell Myeloma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05208307 | — | P2 | recruiting | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma |
| NCT04876248 | — | P2 | active not recruiting | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant |
| NCT04892264 | — | P1 | terminated | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma |
Recurrent Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05847569 | — | P2 | recruiting | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma |
| NCT06232044 | — | P1/P2 | recruiting | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma |
AL Amyloidosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05145816 | — | P1/P2 | recruiting | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis |
| NCT04617925 | EMN27 | P2 | completed | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis |
Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05055063 | — | P1 | recruiting | A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma |
| NCT04680468 | — | P2 | active not recruiting | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma |
Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07224672 | ALANIS | P2 | not yet recruiting | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis |
Primary Immune Thrombocytopenia (ITP) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07019545 | BONSAI | P2 | not yet recruiting | A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY |
Autoimmune Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06413511 | — | P1 | withdrawn | A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease |
Relapsed Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05922501 | ISABELA | P2 | recruiting | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma |
Multiple Myeloma, Refractory (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05493618 | — | P1/P2 | withdrawn | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. |
Myeloma Multiple (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05091372 | — | P2 | recruiting | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma |
Relapsed/ Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05461209 | MonumenTAL-5 | P3 | withdrawn | A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma |
Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05117008 | EMBRACE | P2 | terminated | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma |
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05297240 | RRMM | N/A | unknown | Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain. |
Relapsed Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05060627 | — | P1/P2 | active not recruiting | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide |
Relapsed Plasmablastic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04676360 | — | P2 | terminated | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma |
Plasma Cell Myeloma Refractory (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04643002 | — | P1/P2 | recruiting | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol |
Relapsed Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03732703 | MyDRUG | P1/P2 | completed | Myeloma-Developing Regimens Using Genomics (MyDRUG) |
Belantamab mafodotin pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| PrE1005 | NCT07285239 | P3 | not yet recruiting | Multiple Myeloma | 500 | — |
| DREAMM-10 | NCT06679101 | P3 | recruiting | Multiple Myeloma | 520 | — |
| DREAMM 8 | NCT06956170 | P3 | active not recruiting | Multiple Myeloma | 21 | — |
| DREAMM 8 | NCT04484623 | P3 | active not recruiting | Multiple Myeloma | 302 | PMID 40763276 |
| DREAMM 7 | NCT06868654 | P3 | active not recruiting | Multiple Myeloma | 72 | — |
| DREAMM 7 | NCT06868667 | P3 | active not recruiting | Multiple Myeloma | 24 | — |
| DREAMM 7 | NCT04246047 | P3 | active not recruiting | Multiple Myeloma | 494 | PMID 38828933 |
| DREAMM-3 | NCT04162210 | P3 | active not recruiting | Multiple Myeloma | 325 | PMID 37793771 |
| MonumenTAL-5 | NCT05461209 | P3 | withdrawn | Relapsed/ Refractory Multiple Myeloma | 0 | — |
| ALANIS | NCT07224672 | P2 | not yet recruiting | Amyloidosis | 60 | — |
| DREAMM-16 | NCT07614360 | P2 | not yet recruiting | Multiple Myeloma | 120 | — |
| ISABELA | NCT05922501 | P2 | recruiting | Relapsed Cancer | 50 | — |
| RRMM | NCT07227311 | P2 | recruiting | Multiple Myeloma | 200 | — |
| COSTA | NCT05874193 | P2 | not yet recruiting | Relapsed/Refractory Multiple Myeloma | 33 | PMID 32265930 |
| BONSAI | NCT07019545 | P2 | not yet recruiting | Primary Immune Thrombocytopenia (ITP) | 14 | — |
| DREAMM 14 | NCT05064358 | P2 | completed | Multiple Myeloma | 177 | — |
| EMN27 | NCT04617925 | P2 | completed | AL Amyloidosis | 35 | — |
| EMBRACE | NCT05117008 | P2 | terminated | Refractory Multiple Myeloma | 1 | — |
Terminated and withdrawn Belantamab mafodotin trials (13)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05493618withdrawnPembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
- NCT05065047terminatedBelantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
- NCT04398680withdrawnA Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
- NCT06413511withdrawnA Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease
- NCT05833737terminatedCorneal Findings in Patients Treated With Belantamab Mafodotin
- NCT04896658terminatedBelantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- NCT04676360terminatedBelantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
- NCT05461209withdrawnA Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
- NCT04892264terminatedBelantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
- NCT06655818terminatedSub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
- NCT05117008terminatedMaintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
- NCT06160609terminatedPlatform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
- NCT04549363terminatedCharacterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
All Belantamab mafodotin trials (69)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07285239 | PrE1005 | Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | P3 | not yet recruiting | 500 | PrECOG, LLC. | Jul 2026 |
| NCT05847569 | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma | P2 | recruiting | 62 | Mayo Clinic | Jan 2024 | |
| NCT07224672 | ALANIS | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis | P2 | not yet recruiting | 60 | GlaxoSmithKline | Mar 2026 |
| NCT04822337 | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | P1/P2 | active not recruiting | 70 | Wake Forest University Health Sciences | May 2021 | |
| NCT07609706 | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | P1 | not yet recruiting | 20 | GlaxoSmithKline | Oct 2026 | |
| NCT06679101 | DREAMM-10 | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | P3 | recruiting | 520 | GlaxoSmithKline | Dec 2024 |
| NCT07614360 | DREAMM-16 | Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma | P2 | not yet recruiting | 120 | GlaxoSmithKline | Aug 2026 |
| NCT05922501 | ISABELA | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | P2 | recruiting | 50 | Massachusetts General Hospital | May 2024 |
| NCT07227311 | RRMM | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) | P2 | recruiting | 200 | GlaxoSmithKline | Apr 2026 |
| NCT06232044 | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | P1/P2 | recruiting | 88 | Alliance for Clinical Trials in Oncology | Apr 2025 | |
| NCT05714839 | DREAMM-20 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | P1/P2 | recruiting | 152 | GlaxoSmithKline | Jun 2023 |
| NCT06956170 | DREAMM 8 | All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | P3 | active not recruiting | 21 | GlaxoSmithKline | Feb 2022 |
| NCT04484623 | DREAMM 8 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | P3 | active not recruiting | 302 | GlaxoSmithKline | Oct 2020 |
| NCT05853965 | BELI(E)VE | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | P1/P2 | recruiting | 45 | Universitätsklinikum Hamburg-Eppendorf | Jun 2023 |
| NCT04808037 | BelaRd | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma | P1/P2 | active not recruiting | 66 | Hellenic Society of Hematology | Feb 2021 |
| NCT05789303 | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | P2 | recruiting | 83 | University of Chicago | May 2023 | |
| NCT05874193 | COSTA | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma | P2 | not yet recruiting | 33 | Cristiana Costa Chase, DO | May 2026 |
| NCT06868654 | DREAMM 7 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | P3 | active not recruiting | 72 | GlaxoSmithKline | Jul 2021 |
| NCT06868667 | DREAMM 7 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | P3 | active not recruiting | 24 | GlaxoSmithKline | Jul 2021 |
| NCT04246047 | DREAMM 7 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | P3 | active not recruiting | 494 | GlaxoSmithKline | May 2020 |
| NCT05060627 | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | P1/P2 | active not recruiting | 60 | PETHEMA Foundation | Dec 2021 | |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | P1/P2 | recruiting | 258 | Sanofi | Jan 2021 | |
| NCT05091372 | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | P2 | recruiting | 94 | M.D. Anderson Cancer Center | Dec 2022 | |
| NCT05208307 | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | P2 | recruiting | 34 | Emory University | Jul 2022 | |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant | P2 | active not recruiting | 4 | Roswell Park Cancer Institute | Aug 2024 | |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | P1/P2 | recruiting | 37 | University of Texas Southwestern Medical Center | Feb 2024 | |
| NCT07019545 | BONSAI | A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY | P2 | not yet recruiting | 14 | Hellenic Society of Hematology | Jun 2025 |
| NCT02343042 | STOMP | Selinexor and Backbone Treatments of Multiple Myeloma Patients | P1/P2 | active not recruiting | 300 | Karyopharm Therapeutics Inc | Oct 2015 |
| NCT07150104 | GSK2857916 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM | P1/P2 | active not recruiting | 14 | GlaxoSmithKline | Aug 2022 |
| NCT07150091 | GSK2857916 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | P1/P2 | active not recruiting | 20 | GlaxoSmithKline | Jul 2022 |
| NCT07217184 | GSK2857916 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM | P1/P2 | active not recruiting | 30 | GlaxoSmithKline | Jul 2021 |
| NCT07084896 | GSK2857916 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | P1/P2 | active not recruiting | 106 | GlaxoSmithKline | Jun 2020 |
| NCT04162210 | DREAMM-3 | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | P3 | active not recruiting | 325 | GlaxoSmithKline | Apr 2020 |
| NCT07217119 | GSK2857916 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM | P1/P2 | active not recruiting | 25 | GlaxoSmithKline | Nov 2019 |
| NCT04126200 | DREAMM 5 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | P1/P2 | active not recruiting | 208 | GlaxoSmithKline | Oct 2019 |
| NCT05055063 | A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma | P1 | recruiting | 30 | M.D. Anderson Cancer Center | May 2022 | |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma | P1/P2 | active not recruiting | 24 | Yale University | Feb 2022 | |
| NCT04091126 | DREAMM 9 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | P1 | active not recruiting | 118 | GlaxoSmithKline | Dec 2019 |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | P1/P2 | recruiting | 36 | Hellenic Society of Hematology | Jul 2023 | |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | P1/P2 | not yet recruiting | 48 | Hellenic Society of Hematology | Oct 2022 | |
| NCT05556798 | A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | P1 | active not recruiting | 9 | Memorial Sloan Kettering Cancer Center | Oct 2022 | |
| NCT04680468 | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma | P2 | active not recruiting | 41 | University of Pennsylvania | Jun 2021 | |
| NCT04802356 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | P2 | active not recruiting | 50 | PETHEMA Foundation | Apr 2021 | |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | P1/P2 | unknown | 36 | Hellenic Society of Hematology | Apr 2022 | |
| NCT05064358 | DREAMM 14 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma | P2 | completed | 177 | GlaxoSmithKline | Mar 2022 |
| NCT04398745 | DREAMM12 | A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function | P1 | active not recruiting | 36 | GlaxoSmithKline | Oct 2020 |
| NCT05493618 | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | P1/P2 | withdrawn | 0 | Hackensack Meridian Health | Dec 2022 | |
| NCT05065047 | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma | P1 | terminated | 6 | M.D. Anderson Cancer Center | Jan 2023 | |
| NCT04398680 | DREAMM 13 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function | P1 | withdrawn | 0 | GlaxoSmithKline | Apr 2021 |
| NCT04617925 | EMN27 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | P2 | completed | 35 | Stichting European Myeloma Network | Feb 2021 |
| NCT06413511 | A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease | P1 | withdrawn | 0 | GlaxoSmithKline | Jun 2024 | |
| NCT05833737 | Corneal Findings in Patients Treated With Belantamab Mafodotin | — | terminated | 12 | Medical University of Vienna | Jun 2023 | |
| NCT03732703 | MyDRUG | Myeloma-Developing Regimens Using Genomics (MyDRUG) | P1/P2 | completed | 103 | Multiple Myeloma Research Consortium | Apr 2019 |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | P1/P2 | terminated | 10 | University of Maryland, Baltimore | Dec 2021 | |
| NCT04676360 | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | P2 | terminated | 10 | Jacob Soumerai, MD | Jul 2021 | |
| NCT05461209 | MonumenTAL-5 | A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma | P3 | withdrawn | 0 | Janssen Research & Development, LLC | Oct 2022 |
| NCT03525678 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | P2 | completed | 221 | GlaxoSmithKline | Jun 2018 | |
| NCT03828292 | An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments | P1 | completed | 15 | GlaxoSmithKline | Mar 2019 | |
| NCT05393024 | Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy | — | completed | 78 | Fondazione EMN Italy Onlus | Jul 2022 | |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | P1 | terminated | 5 | Mayo Clinic | Jun 2021 | |
| NCT03544281 | DREAMM 6 | To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | P1/P2 | completed | 153 | GlaxoSmithKline | Sep 2018 |
| NCT06655818 | GSK2857916 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM | P1/P2 | terminated | 4 | GlaxoSmithKline | Mar 2021 |
| NCT05117008 | EMBRACE | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma | P2 | terminated | 1 | Medical College of Wisconsin | Jul 2022 |
| NCT03848845 | DREAMM 4 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) | P1/P2 | completed | 41 | GlaxoSmithKline | Mar 2019 |
| NCT06160609 | GSK2857916 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM | P1/P2 | terminated | 9 | GlaxoSmithKline | Oct 2019 |
| NCT05297240 | RRMM | Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain. | — | unknown | 170 | PETHEMA Foundation | Mar 2022 |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin | P3 | terminated | 16 | GlaxoSmithKline | Dec 2020 | |
| NCT04177823 | RRMM | A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | P1 | completed | 6 | GlaxoSmithKline | Dec 2019 |
| NCT03763370 | Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma | — | available | 0 | GlaxoSmithKline | — |
Belantamab mafodotin clinical trials: frequently asked questions
- How many Belantamab mafodotin clinical trials are there?
- 69 Belantamab mafodotin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 14 are actively recruiting participants. 9 are marked completed.
- Are Belantamab mafodotin clinical trials recruiting in 2026?
- Yes — 14 Belantamab mafodotin trials are actively recruiting in 2026, with 93 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Belantamab mafodotin being studied for?
- Belantamab mafodotin is being studied for Multiple Myeloma, Refractory Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Plasma Cell Myeloma, Corneal Disease and 31 more. The trials are grouped by indication on this page.
- What phase is Belantamab mafodotin in?
- Belantamab mafodotin clinical trials span 10 Phase 3, 18 Phase 2, 11 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Belantamab mafodotin clinical trials?
- The lead sponsor across the most Belantamab mafodotin trials is GlaxoSmithKline, with 28 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Belantamab mafodotinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: